Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT-1 Induction Study in Ulcerative Colitis
2022-500535-36-00Phase 3Withdrawn
- Sponsor
- Abivax
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing OBEFAZIMOD once daily with Placebo once daily (2 arms). Primary endpoint: Clinical remission at week 8 per Modified Mayo Score. Planned start Dec 2022; status: withdrawn.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-500535-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500535-36-00.